Drug Evaluation Committee 104th Assembly of the Clinical Evaluation Section (Part 2) - Innovation and New Challenges
Feb 19, 2021
- About JPMA
- About Medicines
- Committee Updates
- Code Compliance Committee
- Pharmaceutical Industrial Policy Committee
- Distribution Improvement Committee
- Drug Evaluation Committee
- Quality & Technology Committee
- Biopharmaceutical Committee
- Regulatory Affairs Committee
- Intellectual Property Committee
- R & D Committee
- International Affairs Committee
- Public Affairs Committee
- Patient Cooperation Committee
- ICH Project
- APAC Project
- Consumer Consultation Review Committee
- Environmental Issue Committee
- Newsletter
- Newsroom
- The Office of Pharmaceutical Industry Research
- Patients and the General Public (About Medicines)
-
Committee Updates
- Code Compliance Committee
- Pharmaceutical Industrial Policy Committee
- Distribution Improvement Committee
- Drug Evaluation Committee
- Quality & Technology Committee
- Biopharmaceutical Committee
- Regulatory Affairs Committee
- Intellectual Property Committee
- R & D Committee
- International Affairs Committee
- Public Affairs Committee
- Patient Cooperation Committee
- ICH Project
- APAC Project
- Consumer Consultation Review Committee
- Environmental Issue Committee
- About JPMA
- Policies and Activities
-
Voluntary Standards
- Code of Conduct
- JPMA Code of Practice
- Transparency Guideline for the Relation between Corporate Activities and Medical Institutions
- Transparency Guideline for Relationships Between Corporate Activities and Patient Organizations
- Guidelines for the Preparation of Summaries of Product Characteristics for Prescription Drugs (Abbreviation: Preparation Guidelines)
- Clinical Research
- Basic Principles and Guidelines for Action on Biodiversity
- Guidelines on Fair Competition at Meetings of the Japan Pharmaceutical Manufacturers Association
- Agreements, Manuals, and Guidelines
- Newsroom
-
The Office of Pharmaceutical Industry Research
- Social Media Policy
- Website Terms of Use